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Abstract 
Background: Foxp3 is a key regulator of the development and function of regulatory T cells (Tregs), and its expres‑
sion is thought to be T cell‑restricted. We found that B cells in mice can express Foxp3 and B cells expressing Foxp3 
may play a role in preventing the development of collagen‑induced arthritis (CIA) in DBA/1J mice.
Methods: Foxp3 expression was modulated in CD19+ B cells by transfection with shRNA or using an over‑expression 
construct. In addition, Foxp3‑transfected B cells were adoptively transferred to CIA mice. We found that LPS or anti‑
IgM stimulation induced Foxp3 expression in B cells. Foxp3‑expressing B cells were found in the spleens of mice.
Results: Over‑expression of Foxp3 conferred a contact‑dependent suppressive ability on proliferation of responder T 
cells. Down‑regulation of Foxp3 by shRNA caused a profound induction in proliferation of responder T cells. Adoptive 
transfer of Foxp3+CD19+ B cells attenuated the clinical symptoms of CIA significantly with concomitant suppression 
of IL‑17 production and enhancement of Foxp3 expression in CD4+ T cells from splenocytes.
Conclusion: Our data indicate that Foxp3 expression is not restricted to T cells. The expression of Foxp3 in B cells is 
critical for the immunoregulation of T cells and limits autoimmunity in a mouse model.
Keywords: Foxp3, Regulatory B cell, Th17, Arthritis
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
B cells exert a variety of immune functions, including the 
production of immunoglobulins (Igs) and cytokines, the 
presentation of antigens, and the regulation of dendritic 
cells [1–4]. B cells are generally considered to positively 
regulate immune responses by producing antigen(Ag)-
specific antibodies (Abs) and inducing CD4+ T cell acti-
vation [5]. B cells are involved in the development of 
several autoimmune disorders through the production of 
pathogenic Igs [6, 7]. Especially, immune-regulatory roles 
of B cells in autoimmune diseases have been reported 
that specific B cell subsets regulate immune responses 
and participate in the induction of immune tolerance [8, 
9].
The existence of B cells with regulatory properties 
has been widely reported [10–14]. Several studies have 
shown that absence of B cells exacerbated pathologic 
inflammatory responses in autoimmune diseases [12, 14]. 
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inflammation in Experimental Autoimmune Encepha-
lomyelitis [1]. Mizoguchi and colleagues introduced the 
term ‘regulatory B cells (Bregs)’ to designate B cells with 
negative regulatory properties [15]. Experimental studies 
have demonstrated that the absence or loss of Bregs exac-
erbates symptoms in several experimental autoimmune 
disease model including collagen-induced arthritis (CIA) 
[15–21]. Additionally, Bregs showed therapeutic proper-
ties in autoimmune arthritis mice models [18, 22].
Rheumatoid arthritis (RA) is a debilitating autoim-
mune disease characterized by chronic inflammation 
and destruction of the joints has been considered to be 
a Th1 and/or Th17-mediated disease. However, B cells 
also play important roles in the pathogenesis of RA. B 
cells present within the synovial membrane of affected 
joints are involved directly in sustained inflammation in 
the rheumatoid synovium [3], and play a critical role in 
the synthesis of rheumatoid factor (RF) [23]. The thera-
peutic success of B cell depletion using a mAb against 
the B-cell surface molecule CD20 (Rituximab; RTX) has 
brought in a renewed focus on the role of B cells in the 
pathogenesis and control of RA and other autoimmune 
diseases [24, 25]. Interestingly, regulatory B cells have 
also been proposed to play a role in the K/BxN arthri-
tis mouse model, a model in which Igs are required for 
disease development. Furthermore, the number of regu-
latory B cells was negatively correlated with disease 
activity in new onset RA patients [26]. Several different 
Breg subsets have now been identified and characterized 
phenotypically as CD5+ B-1a, CD1d+ marginal zone B 
cells, transitional-2-marginal zone precursor B cells, and 
CD1dhiCD5+CD19hi in mouse models.
The transcription factor Foxp3 is a master regulator of 
Tregs, controlling their development and function. A role 
for Foxp3 in maintaining self tolerance has been shown in 
scurfy mice, and in patients with immunodysregulation, 
polyendocrinopathy, enteropathy, and X-linked (IPEX) 
syndrome as the causative genetic anomaly that results in 
severe autoimmune diseases [27–29]. The expression of 
Foxp3 in conventional T cells confers suppressive activity 
and induces the expression of associated molecules such 
as CD25, cytotoxic T lymphocyte antigen 4 (CTLA4), 
and glucocorticoid-induced TNF receptor-related pro-
tein (GITR) [30–32]. These findings suggest that B cells 
with suppressive activity may also express Foxp3. Foxp3 
expressing CD19(+)CD5(+) B cell population was iden-
tified in human peripheral blood mononuclear cells and 
regulatory properties of this cell type was proposed [33]. 
The Foxp3 expressing regulatory B cells were identified as 
strong suppressors in milk allergy in human.
In the present study, we investigated the existence 
of Foxp3-expressing B cells, and their regulatory roles 
in mice arthritis model, by testing whether they could 
regulate the proliferation of effector T cells in  vitro 
through a cell-to-cell contact-dependent mechanism. 
Furthermore, we found a therapeutic effect of Foxp3+ B 
cells in autoimmune arthritis by performing cell trans-
fer studies in CIA mice, an animal model of RA. We 
observed that the Foxp3+ B cells showed a strong sup-
pressive effect against arthritis in CIA mice.
Methods
Mice
Male DBA/1J mice aged 6–8 weeks were purchased from 
the Charles River Laboratory (Yokohama, Japan). Mice 
were housed in groups of 10 and maintained at a mean 
temperature of 21  °C (±2  °C) on a 12-h light/12-h dark 
cycle, with food and water available ad libitum. All exper-
imental procedures were examined and approved by the 
Animal Research Ethics Committee of the Catholic Uni-
versity of Korea (permit number: CUMC-2009-0044-01), 
which conforms to all National Institutes of Health of the 
USA guidelines. All surgeries were performed under iso-
flurane anesthesia, and all efforts were made to minimize 
suffering.
Cell preparation and culture
The A20 cell line (mouse B cell lymphoma) was pur-
chased from the American Type Culture Collection 
(ATCC; Rockville, MD, USA). Spleens were collected 
for cell preparations from DBA/1J or arthritis mice. To 
purify CD19+ B cells or CD4+ T cells, splenocytes were 
incubated with CD19 or CD4 microbeads (Miltenyi Bio-
tec, Auburn, CA, USA) and isolated on MACS separation 
columns. B cells or T cells determined by staining with 
FITC-labeled anti-CD19 mAb or PE-labeled anti-CD4 
mAb, respectively (BD Biosciences Pharmingen, San 
Diego, CA, USA). These cells were >98 % purity. CD19+ B 
cells or A20 cells were cultured with various stimuli, such 
as 10 µg/ml lipopolysaccharide (LPS; Sigma-Aldrich, St. 
Louis, MO, USA) or 10 µg/ml anti-IgM (Jackson Immu-
noResearch, West Grove, PA, USA) for 72 h.
Flow cytometric analysis
CD19+ B cells were resuspended in 4 % BSA flow buffer 
and blocked with CD16/CD32 Fc antibody (BD Pharmin-
gen). Cells were incubated on ice for 30 min with FITC-
labeled anti-CD19 mAb or PerCP cy5.5-labeled anti-CD4 
mAb (all from eBioscience, San Diego, CA, USA). For 
intracellular staining of Foxp3 and CTLA4, cells were 
fixed, permeabilized, and stained with FITC- or PE-
labeled anti-Foxp3 mAb and/or PE-labeled anti-CTLA4 
mAb (all from eBioscience). Finally, cells were analyzed 
using a FACSCalibur (Becton–Dickinson, San Jose, 
CA, USA). Cells that stained positively for CD4, CD19, 
CD25, IL-17 and Foxp3 were counted visually at higher 
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magnification by four individuals, and the mean values 
were presented in the form of a graph.
Transfection of CD19+ B cells
The Foxp3 open reading frame (ORF) was codon opti-
mized for mammalian codon usage and was synthesized 
by Genscript Corp. (Piscataway, NJ, USA). The Foxp3 
ORF was subcloned into the pcDNA3.1 (+) mamma-
lian expression vector (Invitrogen, Carlsbad, CA, USA), 
digested with Hindlll and Xho l sites. The construct was 
verified by DNA sequencing (Macrogen, Seoul, Korea). 
Foxp3-specific targeting short hairpin RNA (shRNA) was 
purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). For transfection, splenic CD19+ B cells were 
seeded in 24-well plates. Cells were transfected with 
1.5 µg of DNA using poly-MAG and Magneto FACTOR 
plates (Chemicell GmbH, Berlin, Germany), accord-
ing to the manufacturer’s instructions. Cell viability was 
assessed using the Cell Counting kit-8 (CCK-8, Dojindo 
Laboratories, Kumamoto, Japan).
RT‑PCR analysis of mRNA expression
Total RNA was extracted using TRIZOL® Reagent (Inv-
itrogen) and cDNA synthesis was performed using oligo-
dT primers and AMV reverse transcriptase (Promega, 
Mannheim, Germany), according to the manufacturer’s 
instructions. PCR amplification of cDNA aliquots was 
performed by addition of 2.5  mM dNTPs, 2.5  U Taq 
DNA polymerase (Takara, Shiga, Japan), and 0.25  µM 
sense and antisense primers. The following sense and 
antisense primers were used: mice Foxp3, 5′- CCC AGG 
AAA GAC AGC AAC CTT-3′ (sense) and 5′- TTC TCA 
CAA CCA GGC CAC TTG-3′ (antisense), and mice 
β-actin, 5′-GAA ATC GTG CGT GAC ATC AAA G-3′ 
(sense) and 5′-TGT AGT TTC ATG GAT GCC ACA 
G-3′ (antisense). Reactions occurred in a DNA thermal 
cycler (PerkinElmer, Norwalk, CT) and comprised 30–35 
cycles of 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s. 
PCR products were run on a 2.5 % agarose gel and gels 
and visualized under ultraviolet light using a Gel-doc 
1000 (Bio-Rad, Hercules, CA, USA).
Western blot analysis
CD19+ B cell lysates were denatured in SDS, resolved 
by 10  % SDS-PAGE, and transferred to polyvinylidene 
fluoride membranes (Amersham Pharmacia, NJ, USA). 
Membranes were pre-incubated with 5 % skimmed milk 
in TBS for 2 h at room temperature. Primary Abs directed 
against Foxp3 (Santa Cruz Biotechnology), diluted 1/200 
in blocking buffer (5 % skimmed milk in TBS), were then 
added and the samples incubated overnight at 4 °C. After 
the samples were washed for four times in TBST, HRP-
conjugated secondary Abs were added and incubated 
for 1  h at room temperature. Finally, membranes were 
washed in TBST and the hybridized bands were detected 
with an ECL detection kit (Pierce, Rockford, IL, USA).
Confocal immunofluorescence assay
For confocal staining, 7-µm sections of spleen tissue 
was fixed in acetone and blocked with 20  % FCS/PBS. 
After washing, slides were stained using PE or FITC-
labeled anti-Foxp3, PE-labeled anti-IL-17, biotinylated 
anti-CD19, APC-labeled anti-CD25 and FITC, or PerCP 
cy5.5-labeled anti-CD4, followed by streptavidin-FITC. 
After being washed, slides were mounted and visualized 
using a Zeiss microscope (LSM 510 Meta; Carl Zeiss, 
Oberkochen, Germany). Results were mean value of 4 
sections in spleens from 3 animals. We presented repre-
sentative figure.
Suppression assay
CD4+CD25− T cells were isolated from spleens of 
arthritic mice by magnetic bead cell sorting using an 
untouched CD4+ T Cell Isolation Kit II and CD25 Micro-
beads (all from Miltenyi Biotec, Bergisch Gladbach, Ger-
many), according to the manufacturer’s instructions. To 
assess the suppressive activities of Foxp3-transfected 
CD19+ B cells, CD4+CD25−responder T cells (5 × 104/
well) were cultured with a 1:1 ratio of shRNA or Foxp3-
transfected CD19+ B cells (which were stimulated with 
LPS or anti-IgM) in the presence or absence of bovine 
type II collagen (CII) (Chondrex Inc., Redmond, WA, 
USA), in a 100  ng/ml anti-CD3-coated 96-well plate. In 
some cases, Foxp3-transfected CD19+ B cells were placed 
in the inner transwell chamber. During the last 16  h of 
culture, cells were pulsed with 3H-thymidine (1  μCi/
well; MP Biomedicals, Seven Hills, Australia). Cells were 
assessed for thymidine incorporation in a Microbeta 
counter (Wallac Oy 1450 MicroBeta; Wallac, Melbourne, 
Australia).
Induction and clinical assessment of arthritis
CII was dissolved in 0.1 M acetic acid solution (2 mg/ml) 
by gentle rotation at 4  °C overnight. Mice were injected 
intradermally at the base of the tail with 100 μg CII emul-
sified with an equal volume of CFA containing 2  mg/
ml Mycobacterium tuberculosis (Chondrex Inc). On day 
14, a second injection of CII in IFA was administered. 
Arthritic indices were evaluated three times weekly by 
three or more independent investigators until 9  weeks 
after the first immunization. The scale of the arthritis 
index ranged from 0 to 4. Scores were defined as follows: 
0, no evidence of erythema or swelling; 1, erythema and 
mild swelling confined to the mid-foot (tarsal part) or 
ankle joint; 2, erythema and moderate swelling extend-
ing from the ankle to the mid-foot; 3, erythema and 
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moderate swelling extending from the ankle to the meta-
tarsal joints; 4, erythema and severe swelling encompass-
ing the ankle, foot, and digits [34].
Histological assessment of arthritis
At sacrifice, knee joints (mid-tibia to mid-femur) were 
harvested, and the joints were fixed overnight in 4  % 
paraformaldehyde Decalcified limbs were embedded in 
paraffin and sectioned to a 7-µm thickness. Tissues were 
stained with hematoxylin-eosin (H&E), Toluidine blue, 
and Safranin O. For histological evaluation of arthritis, 
sections were evaluated in a blind manner. The scores 
were evaluated as described previously [35].
Adoptive transfer
Splenic CD19+ B cells of naïve mice were purified with 
magnetic beads (Miltenyi Biotec). Purified spleen B 
cells were transfected with mock or Foxp3 over-expres-
sion construct and cultured with LPS for 72  h. Puri-
fied 10  ×  106 Foxp3-transfected CD19+ B cells were 
suspended in a total of 200  μl saline and transferred 
intravenously into mice on days 7 and 28 after CII 
immunization.
Statistical analysis
Experimental values presented are the means ± SD. 
Student’s t tests were performed to calculate the statis-
tical differences between means of different variables, 
and P values less than 0.05 (two-tailed) were considered 
significant.
Results
LPS and IgM stimulation induced Foxp3 expression 
in mouse B cells
To evaluate the effect of LPS and IgM on Foxp3 expres-
sion of B cells, we cultured splenic CD19+ B cells in the 
presence of LPS or IgM for 72  h. Foxp3 expression was 
ascertained by PCR, immunoblotting, and flow cytom-
etry. Increased in Foxp3 mRNA and protein expression 
were observed in both cultured CD19+ primary B cells 
isolated from splenocytes of wild type mice (WT), and 
in a mouse B cell lymphoma line (A20), after LPS or IgM 
mAb stimulation (Fig.  1a, b). Flow cytometric analysis 
of cultured B cells in media alone showed that 0.73 % of 
B cells expressed Foxp3. After stimulation with LPS or 
IgM mAb, more than 10 % of the CD19+ cells expressed 
Foxp3 (Fig. 1c). Additionally, LPS and IgM mAb induced 
an increased level of Foxp3 expression in CD19+ B cells, 
as determined by confocal microscopy (Fig. 1d).
CD19+ Foxp3+ B cells exist in spleens of CIA mice
Our in vitro studies suggested that stimulation with BCR 
or BCR-independent activators induced Foxp3+ in B cells. 
Therefore, these cells may be related to an inflammatory 
environment such as RA. Next, we investigated whether 
B cells that expressed Foxp3 were present in the spleens 
of CIA mice. Foxp3 mRNA and protein expression was 
detected in splenic B cells under basal conditions and 
was further up-regulated by LPS or anti-IgM stimulation 
(Fig.  2a). By confocal microscopy, we identified Foxp3 
expression in splenic CD19+ B cells, although the vast 
majority of Foxp3+ cells were CD4+ T cells (Fig. 2b). We 
observed more CD19+Foxp3+ B cells in CIA than in WT 
DBA/1 mice, the numbers of which peaked at 5  weeks 
post-immunization (Fig.  2c). Foxp3+ B cells peaked at 
5  weeks and resided in the B cell zone up to 11  weeks, 
although the frequency of Foxp3+ B cells at 8 weeks was 
less than at 5 weeks of immunization. Since T cell medi-
ated immune response was occurred before B cell medi-
ated immune response, the number of CD4+Foxp3+ cells 
were more than that of CD19+Foxp3+ cells in 5 weeks of 
immunization. We also detected CD19+Foxp3+ B cells 
in CIA mice (Fig.  2d). These data indicated that Foxp3-
expressing CD19+ B cells exist naturally in the spleens of 
mice under inflammatory conditions such as CIA.
Foxp3‑transfected B cells have suppressor activity in vitro
Foxp3 plays an essential role in the suppressive function 
of Treg cells. Foxp3+ Treg cells inhibit the activation of 
autoreactive T cells in an antigen-specific manner [36]. 
Therefore, we determined whether B cell suppressor 
activity depends on Foxp3 expression. CD19+ B cells 
were transfected with either Foxp3-specific shRNA, or 
an over-expression construct. Foxp3 over-expression led 
to a two-fold up-regulation compared to control upon 
non-stimulation and stimulation with LPS. Cells trans-
fected with shRNA showed low levels of Foxp3 expres-
sion (Fig. 3a). Transfected cells did not undergo apoptosis 
(Fig.  3b). Since CIA is induced by type II collagen, we 
studied that B cells expressing foxp3 can regulate the 
proliferation of type II collagen specific T cells. CD19+ 
B cells transfected with Foxp3 efficiently suppressed the 
proliferation of CD4+ T cells stimulated with CD3 mAb 
in the absence or presence of CII. In contrast, Foxp3-spe-
cific shRNA-transfected cells showed no inhibitory effect 
on T cell proliferation (Fig. 3c). These data showed that 
expression of Foxp3 is induced after BCR stimulation 
by LPS or anti-IgM, and that the suppressive activity of 
CD19+ B cells is due to the expression of Foxp3.
Foxp3+ expressing B cells‑mediated cell 
contact‑dependent suppression of T cell proliferation
To identify whether Foxp3 can reduce T cell proliferation 
in the cell to cell contact, we measured T cell prolifera-
tion using Foxp3 over-expression vector transfected cells. 
The use of an in vitro transwell assay allows confirmation 
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of whether direct contact with Foxp3+CD19+ B cells 
is required for proliferation of CD4+CD25− T cells. 
Responder T cells were cultured with transfected B cells 
either in direct contact or separated by a transwell. The 
suppressor activity of CD19+ B cells transfected with 
Foxp3 was lost in the absence of cell–cell contact (Fig. 4a, 
b). These findings suggest that the suppressor activity of 
Foxp3-expressing B cells occurred via cell–cell contact.
Foxp3‑transfected B cells inhibit autoimmune arthritis 
in mice
RA is an antigen-specific T cell-mediated autoimmune 
disease. Therefore, we tested whether Foxp3-trans-
fected CD19+ B cells could ameliorate the develop-
ment of arthritis in a CIA model. Splenic CD19+ B cells 
transfected with Foxp3 were transferred to DBA/1J mice 
on days 7 and 28 after the first immunization. Disease 
progression was monitored. In control mice, clinical dis-
ease was apparent on day 21 after the first immunization 
and became steadily worse until the end of the experi-
ment (Fig.  5a). Mice receiving Foxp3-tranfected B cells 
had a lower clinical score of the affected arthritic joints 
and a delay in the development of arthritis compared to 
the CIA mice (Fig. 5a, f ). Consistent with clinical obser-
vations, both the cellular infiltrate within the synovium 
and the level of cartilage degeneration were substantially 
lower in the group transfected with Foxp3. CIA mice 
showed a marked synovial thickening, pannus forma-
tion, and cartilage and bone destruction (Fig. 5b). Inter-
estingly, numbers of CD4+Foxp3+CTLA4+ Treg cells 
Fig. 1 Foxp3 is expressed by LPS and anti‑IgM in mouse B cells. Purified CD19+ B cells were isolated from spleens of 6‑ to 8‑week‑old DBA/1J 
mice. CD19+ primary B cells isolated from splenocytes of wild type mice or A20 (mouse B cell line) were stimulated with 10 µg/ml LPS, or 10 µg/
ml anti‑IgM for 72 h. Foxp3 a mRNA and b protein levels were determined by RT‑PCR and western blot, respectively. The optical densities of Foxp3 
bands were normalized to those of β‑actin. The data represent one of three similar experiments. Bar graphs show mean ± SD. Data are repre‑
sentative of three independent experiments. Significant differences between means of cells cultured in media alone and stimulated cultures are 
indicated: *p < 0.05, **p < 0.01 compared with untreated cells. c Whole splenocytes were stained with CD19‑FITC mAb before permeabilization 
and stained using a Foxp3‑PE mAb. Numbers indicate Foxp3+ cell frequencies within CD19+ B cell subsets. The graph on the right represents the 
absolute cell numbers of Foxp3+ Breg cells. Data are representative of three independent experiments. d Confocal microscopic analysis of cultured 
CD4‑deplected splenocytes for Foxp3 (red, PE), and CD19 (green, FITC). Representative images after LPS treatment are shown. Original magnifica‑
tion, ×400
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Fig. 2 CD19+ Foxp3+ B cells exist in spleens of collagen‑induced arthritis (CIA) mice. CIA was induced in 6‑ to 8‑week‑old male DBA/1J mice by 
intradermal immunization in the base of the tail with Cll/CFA emulsion on day 0, followed by a booster injection on day 21, as described in the 
“Methods” section. a Purified B cells isolated from the spleen of CIA mice were cultured with 10 µg/ml LPS or 10 µg/ml anti‑IgM. Following 72 h of 
activation, Foxp3 mRNA (left) and protein (right) levels were determined by RT‑PCR and Western blot, respectively. The optical densities of Foxp3 
bands were normalized to those of β‑actin. b Spleens of DBA/1J or CIA mice (5 weeks after primary CII immunization) were stained with CD19‑FITC, 
CD4‑PerCP cy5.5, and Foxp3‑PE mAbs and analyzed by confocal laser microscopy. The numbers in the graphs indicate the cell count of positive cells 
counted microscopically. c Kinetic analysis of Foxp3‑expressing B cells in the spleens of CIA mice. Original magnification, ×400. d The expression of 
CD19 and Foxp3 in CIA mice splenocytes. The data represent one of three similar experiments. Bar graphs show mean ± SD. Statistical significance 
was defined at *p < 0.05 compared with 3 weeks after immunization, **p < 0.01, ***p < 0.001 compared with untreated cells
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were increased in the lymph nodes and the spleens of 
Foxp3-transfected mice compared to CIA mice (Fig. 5c). 
We also observed that Th17 cell numbers increased in 
the spleen of CIA mice. In contrast, a larger population 
of Foxp3+ Treg cells and a smaller population of Th17 
cells were observed in mice receiving Foxp3-tranfected 
B cells (Fig.  5d, e). Moreover, Foxp3 transfected B cells 
reduced significantly CIA development compared to 
mock transfected B cells. These data suggest that Foxp3-
expressing CD19+ B cells are protective against arthritis 
development.
Discussion
Foxp3 is the most specific marker of regulatory T cells 
[31, 37]. Up to now, Foxp3 expression has been found 
only in CD4+ T cells and in some tumor cell lines [38]. 
Transformation of B cells with EBV was reported to 
express Foxp3, although normal B cells do not express 
Foxp3 [38]. In this study, we showed that Foxp3-express-
ing CD19+ B cells exist in both normal and autoim-
mune arthritis mice. The origins of these B cells and 
how they develop remain unclear. Given the fact that 
Foxp3+CD19+ B cells constitute only a small fraction of B 
cells, transfection of Foxp3 into B cells provides a useful 
method to generate regulatory B cells in  vitro. In vitro-
generated regulatory B cells can be utilized to inhibit the 
progression of ongoing autoimmune processes. Our data 
suggest that transfection of Foxp3 into CD19+ B cells 
induced functional regulatory T cells and suppressed 
effector T cell proliferation. As a result, Foxp3-infected 
B cells delayed the onset of arthritis and suppressed its 
severity in CIA mice.
Regulatory B cell subsets are recognized as an impor-
tant component of the immune system. Several reports 
have shown that regulatory B cells influence T cell activa-
tion and inflammatory responses through the secretion of 
IL-10 [10]. Several phenotypes of regulatory B cells have 
been described. Peritoneal CD5+ B-1a cells are known to 
produce IL-10 [4, 17]. CD5+ B cells also produce IL-10 
upon IL-12 stimulation [39]. Splenic B cells with a CD21+ 
CD23− MZ phenotype from lupus mice produce IL-10 in 
response to CpG stimulation [40]. Splenic CD1dhiCD21+ 
CD23+IgM+ B cells with a T2-MZP phenotype also pro-
duced IL-10 and inhibited the development of CIA [18]. 
Fig. 3 In vitro generation of regulatory B cells with suppressor activity by transfection of Foxp3. Splenic CD19+ B cells from DBA/1J mice were trans‑
fected with Foxp3 shRNA, a Foxp3 over‑expression construct, or control plasmid DNA, and then stimulated with 10 µg/ml LPS, or 10 µg/ml anti‑IgM 
for 72 h. a Relative Foxp3 mRNA levels in Foxp3 shRNA or Foxp3 over‑expressing cells were determined by RT‑PCR using primers specific for Foxp3 
or β‑actin. The relative quantity of Foxp3 was normalized to that of β‑actin in each sample. b Cell viability of CD19+ B cells by MTT assay 24 h after 
plasmid transfection. c Suppression of the proliferation of responder CD4+CD25− T cell stimulation with anti‑CD3 by B cells. CD4+ CD25− T cells 
isolated from the spleens of CIA mice were cultured with Foxp3 shRNA or Foxp3‑transfected CD19+ B cells in the absence (left panel) or presence 
(right panel) of Cll. Proliferation was determined after 3 days of culture by 3H‑thymidine incorporation. Cultures were harvested and cpm were deter‑
mined. Values are the mean ± SD from triplicate cultures. Data represent one of the two independent mice
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IL-10-producing CD1dhiCD5+ regulatory B cell sub-
set showed a suppressive effect against autoimmune 
encephalitis [20]. Recently, a novel subset of IL-10-pro-
ducing regulatory B cells, distinct from MZ or B-1a cells, 
was discovered in the intestine and identified as CD5− 
CD11b− CD21+B cells [41]. Regulatory B cells have been 
demonstrated to exert immunosuppressive functions by 
inducing Tregs or skewing the cytokine profile of effector 
T cells toward an immunosuppressive phenotype [42, 43].
Transcription factors play important roles in the devel-
opment and lineage commitment of lymphocytes. Little 
is known about the transcriptional factors that regulate 
the generation of regulatory B cells. Foxp3 is necessary 
and sufficient for Treg generation and function [44]. Also, 
Foxp3 expression in T cells is known to be restricted. In 
our study, the existence of Foxp3+ Bregs was demon-
strated in mice arthritis model. Foxp3+ may play a role in 
the generation of Bregs, and the over-expression of Foxp3 
in B cells induced regulatory effects.
The BCR plays an important role in the development 
and proliferation of pre-B and B cells [45, 46]. Similarly, 
Foxp3+ regulatory T cell differentiation and function 
in the periphery is also dependent on suboptimal TCR 
stimulation [47]. Our results revealed that expression of 
Foxp3 is induced after BCR stimulation by anti-IgM or 
LPS. The frequency of splenic Foxp3+CD19+ B cells was 
significantly lower in WT than CIA mice. Up-regulation 
of Foxp3 in B cells of CIA mice may be a consequence 
of normal B cell activation under the influence of inflam-
matory conditions. Also, stimulation of Foxp3+CD19+ 
B cells with either LPS or anti-IgM, increased their sup-
pressor activity. Although BCR stimulation induced 
Foxp3, maximal and sustained Foxp3 expression may 
require additional stimulation with ligands such as CD40 
and LPS. Increased Breg cells in CIA animal may rouse 
the question why these Breg cells cannot protect host 
from arthritis. We speculate that increased Breg cells are 
not sufficient in number or function to suppress over-
activated effector T cells in arthritis animal model in vivo. 
There are also other possibilities like increased apoptosis 
of Breg cells in inflammatory conditions. Further studies 
may be needed to prove this hypothesis.
Interestingly, our data showed that adoptive transfer of 
Foxp3+CD19+ B cells-increased the number of Foxp3+ 
Tregs in vivo. Vallerskog et al. [48] reported that Foxp3+ 
T cell numbers were significantly increased in peripheral 
blood of rituximab-infused SLE patients. Alteration of 
T cell populations may be important in the B cell deple-
tion therapy used for autoimmune diseases. Our results 
showed that Foxp3+ Bregs modulated a T cell popula-
tion. The interaction between B and T cells will likely be 
important in the treatment of arthritis and other autoim-
mune diseases.
The mechanism how FoxP3 B cells are working in vivo 
needs be elucidated. We observed that Foxp3 B cells 
secreted large amount of IL-10 and TGF-β (data is not 
shown). IL-10 or TGF-β producing B cells have been 
reported to play important role in regulatory function 
[49–51]. IL-10 inhibits pro-inflammatory cytokine and 
supports regulatory T cell differentiation so play pivotal 
role of immune tolerance.
Conclusion
In summary, we report a significant function of regu-
latory B cells expressing Foxp3 in CIA. The regula-
tory effect of Foxp3+ B cell showed contact-dependent. 
Foxp3+ B cells successfully suppress arthritis and 
induced the Treg cell population. Identification of mech-
anism related to the induction of Treg cells remains an 
Fig. 4 Immunosuppressive action of Foxp3‑trasnfected CD19+ B 
cells was dependent on cell contact. a, b Splenic CD19+ B cells from 
DBA/1J mice were transfected with Foxp3 or control plasmid DNA 
and then stimulated with 10 µg/ml LPS (a) or 10 µg/ml anti‑IgM 
(b) for 72 h. CD4+CD25− T cells were stimulated with anti‑CD3 and 
co‑cultured with transfected B cells either directly (no chamber) or in 
the upper chamber of a transwell plate. Proliferation was determined 
after 3 days of culture by 3H‑thymidine incorporation. Cultures were 
harvested and cpm were determined. Values are the mean ± SD from 
triplicate cultures. Data represent one of the two independent mice
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important area for future study. Therapy using Foxp3+ B 
cells is considered as an intriguing new intervention to 
approach various autoimmune/inflammatory diseases.
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